Klaria Pharmaceuticals updates timeline for announcement of data in pivotal bioequivalence trial of Sumatriptan Alginate Film
Klaria Pharmaceuticals announced today that the top-line data from its pivotal bioequivalence study of Sumatriptan Alginate Film will be available mid-May, 2021. The revised timing is due to factors related to the COVID-19 pandemic.The approval of the study by the regulatory authority MHRA took place on November 30[th], 2020. The first screening of subjects in the study took place on December 15[th], 2020. This timing was a delay of approximately 1.5 months as compared to Klaria’s plan. The reason for the delay in the approval and study start was due to issues within the regulatory